Provectus Therapeutics utilizes a proprietary single-cell drug screening AI platform to conduct high-throughput in vitro drug testing on clinical samples, enabling the prediction of patient-specific drug responses and resistance profiles. This technology addresses the challenge of tumor heterogeneity in precision oncology by providing rapid, actionable insights within 24 hours.
Funding
Funding not disclosed
Founders
Product
Problem
In precision oncology, tumor heterogeneity poses a significant challenge, making it difficult to predict individual patient responses to specific drugs. Traditional drug screening methods often fail to account for this variability, leading to suboptimal treatment decisions and potential drug resistance.
Solution
Provectus Therapeutics offers an AI-driven, single-cell drug screening platform that performs high-throughput in vitro drug testing on patient clinical samples. The platform analyzes over 100 drug responses from a single sample, predicting individual patient response rates and potential drug resistance profiles. By using fully automated robotics, the platform delivers actionable insights within 24 hours, enabling clinicians to make informed, patient-specific treatment decisions. The platform aims to improve treatment efficacy and overcome the challenges posed by tumor heterogeneity.
Target Audience
The primary target audience includes oncologists, pathologists, and pharmaceutical companies seeking to improve drug selection and personalize cancer treatment strategies.
Features
- AI-aided drug testing platform analyzing over 100 drug responses per sample
- High-throughput in vitro drug screening using clinical samples
- Prediction of patient-specific drug response rates and resistance profiles
- Fully automated robotics for sample processing and analysis
- Rapid turnaround time, delivering results within 24 hours